Brexit and possible consequences for clinical research

The CCMO recently published a post on her website where possible consequences of brexit per 30th March 2019 for clinical research with medicinal products are mentioned. These consequence might be, for instance: A new import license may be needed when the production is located in the United Kingdom. A new QP (Qualified Person), located in […]